| Chemical Name||atoltivimab, maftivimab, and odesivimab|
|Dosage Form||Injection (intravenous; atoltivimab mg/maftivimab mg/odesivimab mg per mL: 241.7 mg/ 241.7 mg/ 241.7 mg per 14.5 mL, 16.67 mg/16.67 mg/16.67 mg per mL) |
|Drug Class||Monoclonal antibodies|
Last updated on 12/9/2020
- For the treatment of infection caused by Zaire ebolavirus in adult and pediatric patients, including neonates born to a mother who is RT-PCR positive for Zaire ebolavirus infection.